PCR-Based rAAV DNA Amplification for High-Fidelity ITR Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) face challenges such as long amplification times, complex purification processes, endotoxin contamination, and low viral titers due to the use of bacterial plasmids, particularly with DNA sequences like inverted terminal repeats (ITR) that are ill-suited for plasmid-based amplification.
Innovation Solution
The development of PCR-based methods and systems for amplifying DNA constructs, including the [ITR-cargo-ITR] construct, using specialized PCR primers and osmolytes like betaine to overcome the secondary structure issues of ITR sequences, allowing for high-fidelity and high-yield production of rAAV vectors, including those with single-stranded DNA genomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bacterial plasmids are used to amplify DNA constructs for rAAV production, then large quantities of DNA can be produced, but the amplification time becomes very long (days or weeks) and complex purification steps are required
Solution Approach 1:
The patent replaces the mechanical/biological bacterial plasmid amplification system with a chemical PCR-based amplification system. This substitution enables DNA amplification to occur in hours rather than days or weeks, dramatically reducing amplification time while maintaining the ability to produce large quantities of DNA constructs for rAAV production.
Solution Approach 2:
The patent changes the fundamental parameters of the amplification process by using PCR with optimized cycling conditions, temperatures, and reagents. This allows the DNA amplification to be completed rapidly in a controlled thermal cycling environment rather than relying on slow bacterial growth, thus resolving the time bottleneck.
2Quantity of substance
If bacterial plasmids are used for DNA amplification, then DNA can be produced, but endotoxin contamination and antibiotic resistance gene transfer risks occur
Solution Approach 1:
The patent extracts the DNA amplification process from the bacterial plasmid system entirely, eliminating the source of endotoxin contamination and antibiotic resistance genes. By using PCR-based amplification of synthetic or plasmid-derived templates without bacterial propagation, the harmful byproducts associated with bacterial culture are completely removed.
3Reliability
If inverted terminal repeat (ITR) sequences are used in DNA constructs, then rAAV packaging is enabled, but the sequences form secondary structures that are ill-suited for plasmid-based amplification and lead to high failure rates
Solution Approach 1:
The patent changes the amplification parameters by using PCR with optimized conditions including specific temperatures, buffer compositions, and cycle parameters that prevent the formation of problematic secondary structures in ITR sequences during amplification. This allows reliable amplification of ITR-containing constructs that would otherwise fail in plasmid-based systems.
Solution Approach 2:
The patent replaces the plasmid-based amplification mechanism with PCR-based amplification, which uses different biochemical mechanisms that are not susceptible to the secondary structure problems that plague plasmid replication. This substitution enables successful amplification of ITR sequences that form stable secondary structures incompatible with plasmid maintenance.
4Loss of time
If PCR-based amplification is used to produce DNA constructs with ITR sequences, then amplification time is reduced, but the unique secondary structures of ITR regions were believed to make scalable and accurate amplification impossible
Solution Approach 1:
The patent optimizes PCR parameters including annealing temperature, extension temperature, buffer composition, and cycle conditions to specifically address the challenges posed by ITR secondary structures. These parameter changes enable both rapid amplification and high fidelity, overcoming the previously believed impossibility of accurate PCR amplification of ITR-containing sequences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and scalable production of high-quality rAAV vectors with improved viral titers and therapeutic efficacy by stabilizing DNA polymerases and destabilizing G-C base pairs, reducing side reactions and increasing PCR fidelity.
Implementation Method 1
The PCR master mix contains one or more osmolytes
Implementation Method 2
In some embodiments, the osmolyte may be betaine
Implementation Method 3
the PCR cycling parameters have a combined annealing/extension step at a temperature greater than 70° C.
Data Source
AI summary
The present invention relates to systems and methods to produce recombinant adeno-associated virus (rAAV) utilizing one or more DNA constructs manufactured via polymerase chain reaction (PCR).